Home LiteratureArticle Details
PMID: 8709238 Published · ppublish English Comparative Study Journal Article Research Support, U.S. Gov't, P.H.S.

Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.

Journal of virology ·Vol. 70 ·No. 9 ·1996-09-00 ·Pages 6136-42

Karlsson GB, Gao F, Robinson J, Hahn B, Sodroski J

Abstract

Previous observations that the gp120 envelope glycoprotein contents of some primary, clade B human immunodeficiency virus type 1 (HIV-1) isolates were higher than those of laboratory-passaged HIV-1 isolates suggested the hypothesis that increased envelope glycoprotein spike density or stability contributes to the relative neutralization resistance of the primary viruses. To test this, the structural, replicative, and neutralization properties of a panel of recombinant viruses with HIV-1 envelope glycoproteins from divergent clades were examined in an env complementation assay. In this system, although the spike density and stability of envelope glycoproteins from primary HIV-1 isolates were not greater than those from a laboratory-adapted isolate, relative resistance to neutralizing antibodies and soluble CD4 was observed for the viruses with primary envelope glycoproteins. Thus, neither high envelope glycoprotein spike density nor stability is necessary for the relative neutralization resistance of primary HIV-1 viruses.

MeSH Terms
Antigens, CD/biosynthesis CD4 Antigens/biosynthesis Cell Line Chloramphenicol O-Acetyltransferase/biosynthesis Gene Products, env/biosynthesis Genes, env HIV Antibodies HIV Envelope Protein gp120/biosynthesis,immunology,metabolism HIV Envelope Protein gp41/biosynthesis HIV-1/immunology,isolation & purification,physiology HeLa Cells Humans Kinetics Neutralization Tests Recombinant Fusion Proteins/biosynthesis T-Lymphocytes Transfection Virion/immunology,physiology Virus Replication
Chemicals
Antigens, CD CD4 Antigens Gene Products, env HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp41 Recombinant Fusion Proteins Chloramphenicol O-Acetyltransferase
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Karlsson G B
Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Gao F
Robinson J
Hahn B
Sodroski J
References (48)
48 references, click to expand
  1. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.
    J Virol. 1990 Dec;64(12):5701-7 PMID: 2243375
  2. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.
    Proc Natl Acad Sci U S A. 1988 Apr;85(8):2815-9 PMID: 3357892
  3. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3097-101 PMID: 2014229
  4. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
    AIDS Res Hum Retroviruses. 1991 Jan;7(1):3-16 PMID: 2015114
  5. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.
    Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7056-60 PMID: 1871120
  6. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7802-5 PMID: 1909031
  7. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    J Virol. 1992 Jan;66(1):235-43 PMID: 1727487
  8. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1335-9 PMID: 1741386
  9. Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry.
    Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2223-6 PMID: 1549586
  10. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
    Virology. 1992 Aug;189(2):695-714 PMID: 1386485
  11. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 1992 Sep;66(9):5635-41 PMID: 1380099
  12. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
    J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14 PMID: 8417177
  13. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    J Virol. 1993 Feb;67(2):863-75 PMID: 7678308
  14. Genetic variants of HIV-1 in Thailand.
    AIDS Res Hum Retroviruses. 1992 Nov;8(11):1887-95 PMID: 1489577
  15. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.
    AIDS Res Hum Retroviruses. 1993 Jun;9(6):529-39 PMID: 8347397
  16. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.
    Science. 1993 Nov 19;262(5137):1257-61 PMID: 8235655
  17. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.
    J Virol. 1994 Mar;68(3):1581-5 PMID: 8107219
  18. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.
    J Virol. 1994 Mar;68(3):1586-96 PMID: 8107220
  19. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.
    J Virol. 1994 Mar;68(3):1689-96 PMID: 8107229
  20. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    J Virol. 1994 Aug;68(8):5264-9 PMID: 8035523
  21. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages.
    J Acquir Immune Defic Syndr. 1994 Sep;7(9):908-15 PMID: 7519673
  22. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  23. Neutralization of HIV-1.
    AIDS Res Hum Retroviruses. 1994 Jun;10(6):633-43 PMID: 8074927
  24. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.
    J Virol. 1988 Nov;62(11):4414-9 PMID: 2459416
  25. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.
    J Virol. 1990 May;64(5):2416-20 PMID: 2325207
  26. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.
    J Virol. 1990 Sep;64(9):4390-8 PMID: 2384920
  27. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574-8 PMID: 2395859
  28. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.
    Nature. 1990 Nov 1;348(6296):69-73 PMID: 2172833
  29. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    J Virol. 1995 Jul;69(7):4413-22 PMID: 7769703
  30. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation.
    J Virol. 1995 Aug;69(8):4675-82 PMID: 7609032
  31. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I.
    J Virol. 1995 Oct;69(10):6122-30 PMID: 7666516
  32. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    J Virol. 1996 Jan;70(1):427-44 PMID: 8523556
  33. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.
    J Virol. 1996 Mar;70(3):1651-67 PMID: 8627686
  34. Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes.
    AIDS Res Hum Retroviruses. 1994 May;10(5):561-7 PMID: 7917518
  35. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    J Virol. 1994 Dec;68(12):8350-64 PMID: 7525988
  36. Functional association of cyclophilin A with HIV-1 virions.
    Nature. 1994 Nov 24;372(6504):363-5 PMID: 7969495
  37. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  38. Genetic and phylogenetic analysis of env subtypes G and H in central Africa.
    AIDS Res Hum Retroviruses. 1994 Jul;10(7):877-9 PMID: 7986593
  39. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization.
    AIDS Res Hum Retroviruses. 1994 Nov;10(11):1359-68 PMID: 7888189
  40. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  41. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  42. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
    Cell. 1986 Jun 6;45(5):637-48 PMID: 2423250
  43. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients.
    Cell. 1986 Jul 4;46(1):63-74 PMID: 2424612
  44. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
    Cell. 1986 Nov 7;47(3):333-48 PMID: 3094962
  45. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.
    J Virol. 1987 Feb;61(2):570-8 PMID: 2433466
  46. Use of eukaryotic expression technology in the functional analysis of cloned genes.
    Methods Enzymol. 1987;152:684-704 PMID: 3657593
  47. Biologic features of HIV-1 that correlate with virulence in the host.
    Science. 1988 Apr 1;240(4848):80-2 PMID: 2832945
  48. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.70.9.6136-6142.1996
Published
1996-09-00
Pages
6136-42
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC190636
Subset
IM
Grants
NIAID NIH HHS · AI24755 · United States
NIAID NIH HHS · AI28691 · United States
NCI NIH HHS · CA 06516 · United States
External Links
PubMed source DOI: 10.1128/JVI.70.9.6136-6142.1996 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2